The Role of VEGF Pathways in Human Physiologic and Pathologic Angiogenesis

Journal of Surgical Research

Volumn 159, Issue 1, 2010, Pages 517-527

  Lyons III, John M ^a   Schwimer, Joshua E ^a   Anthony, Catherine T ^a   Thomson, Jessica L ^b   Cundiff, Jason D ^a   Casey, Douglas T ^a   Maccini, Cynthia ^c   Kucera, Paul ^c   Wang, Yi Zarn ^a   Boudreaux, J Philip ^a   Woltering, Eugene A ^a,d  

^a Louisiana Stt Univ Hlth Sci Ctr   (United States)

^b SOUTHERN REGIONAL RESEARCH CENTER   (United States)

^c Providence Cancer Center   (United States)

^d LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

angiogenesis; human; mechanisms; platelet derived growth factor (PDGF); tyrosine kinases; vascular endothelial growth factor (VEGF); VEGF receptors

Indexed keywords

BEVACIZUMAB; FIBRIN; IMC 1121; IMC 18F1; THROMBIN; UNCLASSIFIED DRUG; VASCULOTROPIN 165; VASCULOTROPIN INHIBITOR; VATALANIB;

ANGIOGENESIS; ARTICLE; CANCER TISSUE; CARCINOID; COLON CANCER; CONTROLLED STUDY; FIBRIN CLOT; HUMAN; HUMAN CELL; HUMAN TISSUE; NEOVASCULARIZATION (PATHOLOGY); PLACENTA VEIN; PRIORITY JOURNAL; TUMOR VASCULARIZATION; VEIN;

CELLS, CULTURED; ENDOTHELIAL CELLS; FIBRIN; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; SIGNAL TRANSDUCTION; THROMBIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 76749160237     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2008.12.014     Document Type: Article

References (32)

1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29 6 Suppl. 16 (2002) 15
2. Zakarija A., and Soff G. Update on angiogenesis inhibitors. Curr Opin Oncol 17 (2005) 578
3. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669
4. Pepper M.S., Ferrara N., Orci L., et al. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 189 (1992) 824
5. Ferrara N., and Henzel W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161 (1989) 851
6. Connolly D.T., Heuvelman D.M., Nelson R., et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84 (1989) 1470
7. Gerber H.P., and Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65 (2005) 671
8. Wu Y., Zhong Z., Huber J., et al. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin Cancer Res 21 (2006) 6573
9. Zhu Z., Hattori K., Zhang H., et al. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia 17 (2003) 604
10. Bergsland E.K. Vascular endothelial growth factor as a therapeutic target in cancer. Am J Health Syst Pharm 61 21 Suppl. 5 (2004) S4
11. Nissen N.N., Polverini P.J., Koch A.E., et al. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol 152 (1998) 1445
12. Shifren J.L., Tseng J.F., Zaloudek C.J., et al. Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: Implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. J Clin Endocrinol Metab 81 (1996) 3112
13. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18 (1997) 4
14. Woltering E.A., Lewis J.M., Maxwell IV P., et al. Development of a novel in vitro human tissue-based angiogenesis assay to evaluate the effect of antiangiogenic drugs. Ann Surg 237 (2003) 790
15. Gulec S.A., and Woltering E.A. A new in vitro assay for human tumor angiogenesis: Three-dimensional human tumor angiogenesis assay. Ann Surg Oncol 11 (2004) 99
16. Plouët J., Schilling J., and Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J 8 (1989) 3801
17. Senger D.R., Galli S.J., Dvorak A.M., et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219 (1983) 983
18. Leung D.W., Cachianes G., Kuang W.J., et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246 (1989) 1306
19. Phillips G.D., Stone A.M., Jones B.D., et al. Vascular endothelial growth factor (rhVEGF165) stimulates direct angiogenesis in the rabbit cornea. In vivo 8 (1994) 961
20. Montrucchio G., Lupia E., Battaglia E., et al. Platelet-activating factor enhances vascular endothelial growth factor-induced endothelial cell motility and neoangiogenesis in a murine matrigel model. Arterioscler Thromb Vasc Biol 20 (2000) 80
21. Takeshita S., Zheng L.P., Brogi E., et al. Therapeutic angiogenesis. A single intra-arterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 93 (1994) 662
22. Tolentino M.J., Miller J.W., Gragoudas E.S., et al. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 114 (1996) 964
23. Yamamoto Y., Toi M., Kondo S., et al. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 2 (1996) 821
24. Henry T.D., Annex B.H., McKendall G.R., et al. The VIVA trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 107 (2003) 1359
25. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335
26. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 7 (2001) 987
27. Jost L.M., Gschwind H.P., Jalava T., et al. Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients. Drug Metab Dispos 34 (2006) 1817
28. Wood J.M., Bold G., Buchdunger E., et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60 (2000) 2178
29. Koehne E., Bajetta E., Lin E., et al. Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). J Clin Oncol 24 (2006) 18S abstract 3509
30. Lin Y.S., Mguyen C., Mendoza J.L., et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288 (1999) 371
31. Gordon M.S., Margolin K., Talpaz M., et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19 (2001) 843
32. Posey J.A., Ng T.C., Yang B., et al. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 9 (2003) 1323